| pubmed-article:1417069 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1417069 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1417069 | lifeskim:mentions | umls-concept:C0027950 | lld:lifeskim |
| pubmed-article:1417069 | lifeskim:mentions | umls-concept:C0033860 | lld:lifeskim |
| pubmed-article:1417069 | lifeskim:mentions | umls-concept:C0015137 | lld:lifeskim |
| pubmed-article:1417069 | lifeskim:mentions | umls-concept:C0085416 | lld:lifeskim |
| pubmed-article:1417069 | lifeskim:mentions | umls-concept:C1882115 | lld:lifeskim |
| pubmed-article:1417069 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:1417069 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:1417069 | pubmed:dateCreated | 1992-11-6 | lld:pubmed |
| pubmed-article:1417069 | pubmed:abstractText | During a therapeutic trial to treat psoriasis with either etretinate or cyclosporin A (CyA) we measured the respiratory burst activity of polymorphonuclear leukocytes (PMN). Six patients received 0.5-0.75 mg/kg etretinate and 14 patients 2.5-5.0 mg/kg CyA over a period of 10 weeks. The extent of psoriasis was graded by the psoriasis area-and-severity index (PASI score). The respiratory burst of PMN isolated from the peripheral blood was measured employing luminol-enhanced chemiluminescence at weeks 0, 3 and 10 and compared with that of 26 healthy control individuals. PMN were stimulated with zymosan particles, aggregated immunoglobulin (aggIg) and concanavalin A (ConA). Both treatment regimens improved psoriasis; at 10 weeks there was an approximate 40% PASI score reduction under etretinate and an 80% improvement under CyA. Before treatment the respiratory burst was abnormally high under stimulation with the three stimuli in patients (p = 0.021 to less than 0.0001). After 3 to 10 weeks PMN activity normalized in all patients and even tended to drop below values correlating with an improvement in skin lesions. We conclude that the elevated respiratory burst of PMN in psoriasis normalizes under treatment with both etretinate and CyA. | lld:pubmed |
| pubmed-article:1417069 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1417069 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1417069 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1417069 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1417069 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1417069 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1417069 | pubmed:issn | 0340-3696 | lld:pubmed |
| pubmed-article:1417069 | pubmed:author | pubmed-author:MorschesBB | lld:pubmed |
| pubmed-article:1417069 | pubmed:author | pubmed-author:FärberLL | lld:pubmed |
| pubmed-article:1417069 | pubmed:author | pubmed-author:SchopfR ERE | lld:pubmed |
| pubmed-article:1417069 | pubmed:author | pubmed-author:RehderMM | lld:pubmed |
| pubmed-article:1417069 | pubmed:author | pubmed-author:HöcherJJ | lld:pubmed |
| pubmed-article:1417069 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1417069 | pubmed:volume | 284 | lld:pubmed |
| pubmed-article:1417069 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1417069 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1417069 | pubmed:pagination | 227-31 | lld:pubmed |
| pubmed-article:1417069 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:meshHeading | pubmed-meshheading:1417069-... | lld:pubmed |
| pubmed-article:1417069 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1417069 | pubmed:articleTitle | Etretinate or cyclosporin-A treatment normalizes the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis. | lld:pubmed |
| pubmed-article:1417069 | pubmed:affiliation | Universitäts-Hautklinik, Mainz, Federal Republic of Germany. | lld:pubmed |
| pubmed-article:1417069 | pubmed:publicationType | Journal Article | lld:pubmed |
